Two biotech names on Josh Brown's Best Stocks list are making meaningful highs this summer

Skip NavigationMarketsPre-MarketsU.S. MarketsCurrenciesPrediction MarketsCryptocurrencyFutures & CommoditiesBondsFunds & ETFsBusinessEconomyFinanceHealth & ScienceMediaReal EstateEnergyClimateTransportationInvestigationsIndustrialsRetailWealthSportsLifeSmall BusinessInvestingPersonal FinanceFintechFinancial AdvisorsOptions ActionETF StreetBuffett ArchiveEarningsTrader TalkTechCybersecurityAIEnterpriseInternetMediaMobileSocial MediaCNBC Disruptor 50Tech GuidePolitics & PolicyWhite HousePolicyDefenseCongressExpanding OpportunityVideoLatest VideoFull EpisodesLivestreamLive AudioLive TV ScheduleCNBC PodcastsCEO InterviewsCNBC DocumentariesDigital OriginalsWatchlistInvesting ClubTrust PortfolioAnalysisTrade AlertsMeeting VideosHomestretchJim's ColumnsEducationSubscribePROPro NewsJosh BrownMike SantoliCalls of the DayMy PortfolioLivestreamFull EpisodesStock ScreenerMarket ForecastOptions InvestingChart InvestingSubscribeLivestreamMenuMake ItselectUSAINTLLivestreamSearch quotes, news & videosLivestreamWatchlistSIGN INCreate free accountMarketsBusinessInvestingTechPolitics & PolicyVideoWatchlistInvesting ClubPROLivestreamMenuJosh Brown’s Best Stocks in the MarketPro Stock PicksTwo biotech names on Josh Brown's Best Stocks list are making meaningful highs this summerPublished Mon, Aug 3 202611:18 AM EDTJosh BrownSean RussoWATCH LIVE(This is The Best Stocks in the Market , brought to you by Josh Brown and Sean Russo of Ritholtz Wealth Management.) Josh — Psst, you want to hear more about AI capex? I'm messing with you, I know you would rather watch your parents kiss than listen to another monologue about tokens and data centers and GPUs. So we're going to skip all that today and take a look at an area of the market where traders are escaping to. New stories, new set-ups with plenty of innovation and growth. Come with me to the Land of Biotech, where the charts are pointing north and the air is fresh and clean. Today we've got two names from the Best Stocks in the Market list that are making meaningful highs this summer. Incyte (INCY) and Biogen (BIIB) are two of the longest-lived publicly traded biotech companies we have. Incyte was founded in 1991 and came public two years later. Biogen was formed in 1978 and has been public since 1983! Before we show you the one-year technical charts, I want you to have the context of where these stocks have come from. In the case of Incyte, it briefly eclipsed those old late 1990's era bubble highs a decade ago and is now seeking to challenge them once again. Let me emphasize that this is a fundamentally driven comeback story. Take a look at what earnings per share has done (orange line) since the last time Incyte traded up here. This stock has earned it. Biogen is a little different. In 2024, the stock broke a decade's worth of support and is only now on the verge of reclaiming it. That old floor of $200 is now back in play, as you can see below. Sean's going to catch you up on these names along with our usual high-level look at the whole list. I will be back with the risk management afterward. As of Aug 3, there are 210 names on The Best Stocks in the Market list. Top sector ranking: Top industries: Top 5 best stocks by relative strength: Sector spotlight: Biotech Incyte Corp. (INCY): Sean — We have written about biotech a few times on this column, most recently in March of this year, covering AMGN and ABBV. AMGN has been a laggard since then but ABBV is 13% higher, riding a wave of biotech breakouts in the first half of the year. The thesis from March hasn't changed much. Biotech is very much a HALO trade. Drug manufacturing requires specialized facilities, biologic infrastructure, Food and Drug Administration approvals, patent exclusivity and clinical trials — none of which can be vibe-coded. Meanwhile, AI is culling the most expensive parts of the value chain in biotech. That includes identifying targets, designing treatments and running trials more efficiently. Now to the stocks. Incyte is a $2